FI104233B1 - Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi - Google Patents

Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi

Info

Publication number
FI104233B1
FI104233B1 FI920132A FI920132A FI104233B1 FI 104233 B1 FI104233 B1 FI 104233B1 FI 920132 A FI920132 A FI 920132A FI 920132 A FI920132 A FI 920132A FI 104233 B1 FI104233 B1 FI 104233B1
Authority
FI
Finland
Prior art keywords
vaccine compositions
preparation
compositions containing
interleukins
interleukin
Prior art date
Application number
FI920132A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI920132A0 (fi
FI104233B (fi
Inventor
Subramonia Pillai
Garvin Bixler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI920132A0 publication Critical patent/FI920132A0/fi
Application granted granted Critical
Publication of FI104233B publication Critical patent/FI104233B/fi
Publication of FI104233B1 publication Critical patent/FI104233B1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI920132A 1989-07-14 1992-01-13 Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi FI104233B1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14
US37974289 1989-07-14
PCT/US1990/003982 WO1991001143A1 (en) 1989-07-14 1990-07-16 Stable vaccine compositions containing interleukins
US9003982 1990-07-16

Publications (3)

Publication Number Publication Date
FI920132A0 FI920132A0 (fi) 1992-01-13
FI104233B FI104233B (fi) 1999-12-15
FI104233B1 true FI104233B1 (fi) 1999-12-15

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920132A FI104233B1 (fi) 1989-07-14 1992-01-13 Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi

Country Status (12)

Country Link
EP (1) EP0482076B1 (de)
JP (2) JP3485184B2 (de)
KR (1) KR0177179B1 (de)
AT (1) ATE121629T1 (de)
AU (1) AU648509B2 (de)
CA (1) CA2063587C (de)
DE (1) DE69018990T2 (de)
DK (1) DK0482076T3 (de)
ES (1) ES2075900T3 (de)
FI (1) FI104233B1 (de)
NO (1) NO301577B1 (de)
WO (1) WO1991001143A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
ZA919907B (en) * 1990-12-19 1992-08-26 Schering Corp Use of il-4 to enhance immune response to immunogens in vaccines
JPH07500813A (ja) * 1991-05-13 1995-01-26 リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア リポソーム多糖体ワクチン
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
EP0655927B1 (de) * 1992-08-10 1997-04-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Interleukin-4 stimulierter t-lymphozyten-zelltod
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
DE69735856T2 (de) * 1996-05-31 2006-11-16 National University Of Ireland Maynooth, Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU1813701A (en) 1999-12-03 2001-06-12 Celltech Chiroscience Limited Interleukin-1 muteins useful as vaccine adjuvants
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007039584A1 (en) * 2005-09-30 2007-04-12 Lipoxen Technologies Limited Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
CA2655080A1 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
DK2925297T3 (en) * 2012-11-02 2017-10-02 Cytuvax COMPOSITION COMPREHENSIVE CYTOCHINE MACROAGGERATES
JP7478144B2 (ja) * 2018-10-12 2024-05-02 セラム インスティチュート オブ インディア プライベイト リミテッド 低減用量の不活化ポリオウイルスを含む混合ワクチン組成物およびそれを調製するための方法
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
EP4232070A1 (de) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Verfahren zur induktion von stammzellenmobilisierung
EP4236989A1 (de) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Verwendung von interleukin-7 zur behandlung des coronavirus
EP4240408A1 (de) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus einem il-7-protein und einem nukleotidimpfstoff
AU2022283271A1 (en) 2021-05-24 2023-12-07 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250099542A1 (en) 2021-12-30 2025-03-27 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
FI920132A0 (fi) 1992-01-13
EP0482076B1 (de) 1995-04-26
WO1991001143A1 (en) 1991-02-07
NO920161D0 (no) 1992-01-13
ATE121629T1 (de) 1995-05-15
DK0482076T3 (da) 1995-07-17
FI104233B (fi) 1999-12-15
JP3485184B2 (ja) 2004-01-13
CA2063587C (en) 2005-08-30
KR0177179B1 (ko) 1999-03-20
DE69018990T2 (de) 1995-12-14
ES2075900T3 (es) 1995-10-16
AU6050090A (en) 1991-02-22
EP0482076A1 (de) 1992-04-29
AU648509B2 (en) 1994-04-28
DE69018990D1 (de) 1995-06-01
JP2004002463A (ja) 2004-01-08
JPH04506663A (ja) 1992-11-19
KR920703103A (ko) 1992-12-17
NO920161L (no) 1992-03-05
CA2063587A1 (en) 1991-01-15
NO301577B1 (no) 1997-11-17

Similar Documents

Publication Publication Date Title
FI104233B1 (fi) Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
GB8403921D0 (en) Preparation of lyophilized adsorbed polyvalent vaccines
ES2092306T3 (es) Adyuvante para vacunas.
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
IT1164858B (it) Procedimento per la preparazione di vaccini a base di virus con proteine superficiali ricombinanti e prodotto ottenuto
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
NO924103L (no) Anvendelse av antistoffholdige preparater for immunundertrykkelse
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
NO165478C (no) Fremgangsmaate for fremstilling av antigeniske preparater.
EP0994721A4 (de) Nervenwachstumsfaktor als impfstoffadjuvans
DK1053017T3 (da) Vacciner omfattende interleukin-12 og herpes simplex virusantigen
NZ189756A (en) Muramyl peptides antigens covalently bonded to muramyl-peptides medicaments and vaccines
NZ203190A (en) Vaccines of infections bronchitis virus
CA2123222A1 (en) Gram-negative bacterial vaccines
ZA813479B (en) Process for the isolation of viral glycoproteic antigens and its application to the preparation of vaccines
FI915702A7 (fi) Peptidejä ja niistä johdettuja vasta-aineita HTLV-1 infektion vastaise n rokotuksen määrittämiseksi
AU8298991A (en) Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
SE8404334L (sv) 16-fluoro-16,17-didehydro-prostanoider och forfarande for deras framstellning
IT1135680B (it) Procedimento per la manipolazione di prodotti stampati,come pure mezzi e dispositivo per l'esecuzione dello stesso
IL106407A0 (en) Antigens,vaccines containing them and their preparation
ATE44651T1 (de) Immunogene protein- oder peptidkomplexe enthaltende vakzine.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: AMERICAN CYANAMID COMPANY

MA Patent expired